
Life Sciences Law Update
Kevin C. Clayton
Partner Corporate & Finance
Legal500 commends Kevin noting that he is ‘responsive; gives thoughtful advice, is very knowledgeable and has a good sense of the market‘. In addition to his two decades of advising on mergers and acquisitions and financing transactions, Kevin also has years of experience managing a wide array of commercial matters and complex contracting arrangements, such as joint venture, license, supply, distribution, collaboration, manufacturing, service, employment, and consulting agreements.
While Kevin often represents emerging and growth-stage companies on formation, financing, commercial, and acquisition matters, he also advises later-stage and public companies, particularly with respect to investment, acquisition, joint venture and licensing transactions.
Kevin represents clients in various industry sectors, but has particular experience with matters in the life sciences and technology sectors.
Additionally, Kevin is currently a lecturer on corporate transactions at the University of Virginia School of Law.
Advising Ford Motor Company on Volkswagen AG's US$2.6bn investment into Ford's autonomous vehicle platform company, Argo AI, and certain venture investments.
Represented a publicly traded biotechnology company in several acquisitions and divestitures and numerous strategic venture investments.
Represented RTW Investments in multiple venture investments.
Represented Paladin Capital on multiple venture investments.
Represented B&A in its partnership with Battle Investments Group and its strategic recapitalization with DFW Capital Partners.
Represented American Institutes for Research in the sale of its Assessment Division to Cambium Learning and its acquisition of Impaq LLC.
Represented Daimler AG in its investment in Via Transportation, Inc.
Represented Gilead Sciences and Kite Pharma in multiple venture investments.
Represented OptiNose, Inc. in its US$37m Series D financing, prior equity and debt financings, and general corporate matters.
Represented Fred Hutchinson Cancer Research Center in Juno Therapeutics, Inc.'s formation and US$176m Series A financing, US$134m Series B financing, and related matters.
Represented Avidea Technologies in its acquisition by Vaccitech PLC.
Represented New Enterprise Associates in multiple venture capital investments.
Represented Dental Care Alliance, LLC in its sale to Harvest Partners, LP.
Represented Xora Innovation in numerous venture invesments.
Represented Applied Materials Ventures in multiple venture investments.
Represented PhishMe, Inc. in its US$42m Series C financing, prior equity and debt financings, general corporate matters, and its transaction with Malcovery Security, LLC.
Represented New York University in connection with Spin Transfer Technologies, Inc.'s US$70m financing and other similar transactions.
Represented a luxury vacation club in a variety of equity financings, mortgage-backed debt financings, and acquisitions.
Represented Orbit Fab, Inc. in several financing rounds.
Represented Conceal Inc. in several financing rounds.
Represented RangeForce, Inc. in several financing rounds.